Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript May 9, 2024 Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15985 EPS, expectations were $-0.06. Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning […]
Comprehensive Analysis of Amicus Therapeutics' First Quarter Financial Performance
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.